PREZCOBIX(DARUNAVIR+COBICISTAT) & EVOTAZ ( ATAZANAVIR + COBICISTAT) APPROVED BY FDA TO TREAT HIV SINGLE /COMBINED
- Get link
- Other Apps
PREZCOBIX(DARUNAVIR+COBICISTAT) & EVOTAZ ( ATAZANAVIR + COBICISTAT) APPROVED BY FDA TO TREAT HIV SINGLE /COMBINED
PROF.DRRAM ,HIV/AIDS,SEX Diseases,Deaddiction & Hepatitis Expert
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
Prezcobix, a once-daily combination drug, was approved by the U.S. Food and Drug Administration (FDA), for the treatment of HIV in adults.
The new drug contains 800 mg of the protease inhibitor darunavir (Prezista) and 150 mg of the pharmacokinetic booster cobicistat (Tybost). Prezcobix is recommended to be taken once a day with food, and in conjunction with other antiretroviral agents.
Before this another single-tablet drug contains 300 mg of the protease inhibitor atazanavir (Reyataz) and 150 mg of the pharmacokinetic booster cobicistat (Tybost) was approoved by FDA. Evotaz is recommended to be taken once a day with food, and in conjunction with other antiretroviral agents.
One Evotaz tablet provided similar levels of atazanavir when compared to taking atazanavir and cobicistat separately, according to the FDA press release.
The new drug contains 800 mg of the protease inhibitor darunavir (Prezista) and 150 mg of the pharmacokinetic booster cobicistat (Tybost). Prezcobix is recommended to be taken once a day with food, and in conjunction with other antiretroviral agents.
Before this another single-tablet drug contains 300 mg of the protease inhibitor atazanavir (Reyataz) and 150 mg of the pharmacokinetic booster cobicistat (Tybost) was approoved by FDA. Evotaz is recommended to be taken once a day with food, and in conjunction with other antiretroviral agents.
One Evotaz tablet provided similar levels of atazanavir when compared to taking atazanavir and cobicistat separately, according to the FDA press release.
A previous study showed that cobicistat was non-inferior to ritonavir (Norvir) when used to boost atazanavir or darunavir,while another study found that cobicistat was well-tolerated by HIV-positive patients with mild to moderate renal impairment who made the switch from ritonavir as a booster.
In another study comparing safety profiles, the most common side effects when taking atazanavir with cobicistat were jaundice (13%), ocular icterus (15%) and nausea (12%). These side effects were similar for patients taking atazanavir with ritonavir, according to the FDA press release.
In another study comparing safety profiles, the most common side effects when taking atazanavir with cobicistat were jaundice (13%), ocular icterus (15%) and nausea (12%). These side effects were similar for patients taking atazanavir with ritonavir, according to the FDA press release.
Comments
Post a Comment